Peer-reviewed veterinary case report
CB1 receptor blocker stops energy drop during weight loss in obese
By Strack, Alison M et al.·Published in Metabolism: clinical and experimental·2012·Merck, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss.
- Species:
- dog
Plain-English summary
A group of obese beagles was treated with a medication that blocks a specific receptor (CB1R) to see if it could help them lose weight more effectively than just cutting back on food. After four weeks, the dogs that received the medication lost more weight compared to those on a restricted diet, and their energy levels remained higher. The study found that the medication not only helped with weight loss but also affected how much food the dogs wanted to eat. This suggests that blocking the CB1R could be a helpful approach for managing obesity in dogs.
People also search for: dog weight loss medication · obese beagle diet · how to help my dog lose weight
Abstract
Pharmacologic inhibition of the cannabinoid-1 receptor (CB1R) in rodent models leads to weight loss and time-dependent changes in energy balance. This study evaluated the effects of CB1R inhibition on weight loss, energy expenditure (EE), and food intake (FI) in an obese canine model following 4 weeks of treatment. Eighteen maintenance-fed obese beagles were evenly and randomly allocated to a CB1R inverse agonist (AM251) (2 mg/kg), a 70% food-restricted (FR) diet, or a control group (C). Evaluations included body weight and composition (dual-energy x-ray absorptiometry scan), EE (doubly labeled water), and FI. Change in body mass at week 4 was significantly greater (P < .050) in the AM251 (-1476.7 g) and FR groups (-1100.0 g) than in the C group (-228.3 g). Food intake was decreased from week 2 onward in the FR and AM251 groups (P < .05). Absolute and lean mass-adjusted EEs were decreased only in the FR group (P < .01); EE in the AM251 group was greater (P < .05) than that in the FR group. Pharmacologic inhibition of CB1R in a canine model led to sustained effects on FI and EE. Weight loss was greater with AM251 than could be accounted for by food restriction (∼25%), an effect likely mediated by the EE response to CB1R inhibition.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22001334/